dc.creator | Lagoumintzis G., Chasapis C.T., Alexandris N., Kouretas D., Tzartos S., Eliopoulos E., Farsalinos K., Poulas K. | en |
dc.date.accessioned | 2023-01-31T08:48:17Z | |
dc.date.available | 2023-01-31T08:48:17Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.1016/j.fct.2021.112009 | |
dc.identifier.issn | 02786915 | |
dc.identifier.uri | http://hdl.handle.net/11615/75632 | |
dc.description.abstract | SARS-CoV-2 is the coronavirus that originated in Wuhan in December 2019 and has spread globally. Studies have shown that smokers are less likely to be diagnosed with or be hospitalized for COVID-19 but, once hospitalized, have higher odds for an adverse outcome. We have previously presented the potential interaction between SARS-CoV-2 Spike glycoprotein and nicotinic acetylcholine receptors (nAChRs), due to a “toxin-like” epitope on the Spike glycoprotein, with homology to a sequence of a snake venom toxin. This epitope coincides with the well-described cryptic epitope for the human anti-SARS-CoV antibody CR3022. In this study, we present the molecular complexes of both SARS-CoV and SARS-CoV-2 Spike glycoproteins, at their open or closed conformations, with the model of the human α7 nAChR. We found that all studied protein complexes' interface involves a large part of the “toxin-like” sequences of SARS-CoV and SARS-CoV-2 Spike glycoproteins and toxin binding site of human α7 nAChR. Our findings provide further support to the hypothesis about the protective role of nicotine and other cholinergic agonists. The potential therapeutic role of CR3022 and other similar monoclonal antibodies with increased affinity for SARS-CoV-2 Spike glycoprotein against the clinical effects originating from the dysregulated cholinergic pathway should be further explored. © 2021 Elsevier Ltd | en |
dc.language.iso | en | en |
dc.source | Food and Chemical Toxicology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85100078692&doi=10.1016%2fj.fct.2021.112009&partnerID=40&md5=66dcaeb052fa81e009dc330b10168e7c | |
dc.subject | angiotensin converting enzyme 2 | en |
dc.subject | bungarotoxin receptor | en |
dc.subject | coronavirus spike glycoprotein | en |
dc.subject | SARS CoV 2 spike glycoprotein | en |
dc.subject | SARS CoV spike glycoprotein | en |
dc.subject | unclassified drug | en |
dc.subject | bungarotoxin receptor | en |
dc.subject | coronavirus spike glycoprotein | en |
dc.subject | epitope | en |
dc.subject | monoclonal antibody | en |
dc.subject | nicotine | en |
dc.subject | nicotinic agent | en |
dc.subject | snake venom | en |
dc.subject | spike glycoprotein, SARS-CoV | en |
dc.subject | virus antibody | en |
dc.subject | amino acid sequence | en |
dc.subject | Article | en |
dc.subject | binding affinity | en |
dc.subject | binding site | en |
dc.subject | controlled study | en |
dc.subject | coronavirus disease 2019 | en |
dc.subject | cryoelectron microscopy | en |
dc.subject | enzyme inhibition | en |
dc.subject | human | en |
dc.subject | hydrogen bond | en |
dc.subject | molecular docking | en |
dc.subject | molecular model | en |
dc.subject | nonhuman | en |
dc.subject | protein expression | en |
dc.subject | protein protein interaction | en |
dc.subject | sequence alignment | en |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | en |
dc.subject | antibody combining site | en |
dc.subject | chemistry | en |
dc.subject | metabolism | en |
dc.subject | non-neuronal cholinergic system | en |
dc.subject | pandemic | en |
dc.subject | prevention and control | en |
dc.subject | protection | en |
dc.subject | protein conformation | en |
dc.subject | SARS coronavirus | en |
dc.subject | sequence homology | en |
dc.subject | signal transduction | en |
dc.subject | smoking | en |
dc.subject | virology | en |
dc.subject | alpha7 Nicotinic Acetylcholine Receptor | en |
dc.subject | Amino Acid Sequence | en |
dc.subject | Antibodies, Monoclonal | en |
dc.subject | Antibodies, Viral | en |
dc.subject | Binding Sites, Antibody | en |
dc.subject | COVID-19 | en |
dc.subject | Epitopes | en |
dc.subject | Humans | en |
dc.subject | Models, Molecular | en |
dc.subject | Nicotine | en |
dc.subject | Nicotinic Agonists | en |
dc.subject | Non-Neuronal Cholinergic System | en |
dc.subject | Pandemics | en |
dc.subject | Protective Factors | en |
dc.subject | Protein Conformation | en |
dc.subject | SARS Virus | en |
dc.subject | SARS-CoV-2 | en |
dc.subject | Sequence Homology | en |
dc.subject | Signal Transduction | en |
dc.subject | Smokers | en |
dc.subject | Smoking | en |
dc.subject | Snake Venoms | en |
dc.subject | Spike Glycoprotein, Coronavirus | en |
dc.subject | Elsevier Ltd | en |
dc.title | Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins | en |
dc.type | journalArticle | en |